Bioxytran (OTCMKTS:BIXT – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Bioxytran and uniQure, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bioxytran | 0 | 0 | 0 | 0 | 0.00 |
| uniQure | 1 | 6 | 10 | 0 | 2.53 |
uniQure has a consensus target price of $42.83, indicating a potential upside of 53.69%. Given uniQure’s stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Bioxytran.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bioxytran | N/A | N/A | -$2.12 million | ($0.02) | -1.55 |
| uniQure | $16.10 million | 109.18 | -$198.97 million | ($3.48) | -8.01 |
Bioxytran has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Bioxytran, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Bioxytran and uniQure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bioxytran | N/A | N/A | -737.48% |
| uniQure | -1,154.42% | -145.81% | -27.15% |
Insider & Institutional Ownership
78.8% of uniQure shares are held by institutional investors. 70.0% of Bioxytran shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Bioxytran has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
Summary
Bioxytran beats uniQure on 7 of the 13 factors compared between the two stocks.
About Bioxytran
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
